Download PDF
Thromb Haemost 1965; 13(02): 531-542
DOI: 10.1055/s-0038-1656298
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The in Vitro Anticoagulant Activity of Human Plasma Lipids[*]

J Cohen   **
1   Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
,
C. F Reed
1   Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
,
S. B Troup
1   Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

The present report describes the in vitro inhibition of prothrombin consumption by lipid extracted from normal human platelet-poor plasma. Pro-coagulant lipids and the test plasma lipids were dissolved in the same solvent and evaporated to dryness. The dried lipid mixture was emulsified in platelet-poor plasma, and the plasma clotted by recalcification. Inhibition of prothrombin consumption by plasma lipid was observed when the ratio of plasma lipid to procoagulant lipid equaled or exceeded 5:1. The inhibitory effect of plasma lipid on prothrombin consumption was not observed when procoagulant activity was provided by intact platelets or platelet granules.

Human plasma lipids have been fractionated on silicic acid columns to permit identification of the plasma lipid component responsible for the inhibition of prothrombin consumption. The inhibitory activity is present in a lipid fraction which is 95% lecithin. Other plasma lipid components exhibit little or no inhibitory activity.

* These studies were supported in part by Grant H-04167 (hem) from the National Heart Institute, Bethesda, Maryland, and in part by contract DA-49-007-MD-632, Office of the Surgeon General, Department of the Army.


** Trainee under Training Grant 5-T1-am 5113-07, NI AMD, National Institutes of Health, Bethesda, Maryland.


 

  • References

  • 1 Zak E. Studien zur Blutgerinnungslehre. Arch. exp. Path. Pharmakol. 74: 1 1913;
    PubMedGoogle Scholar
  • 2 Chargajf E. Studies on chemistry of blood coagulation; lipid inhibitor of blood clotting occurring in mammalian tissue. J. Biol. Chem. 121: 175 1937;
    PubMedGoogle Scholar
  • 3 de Sütö-Nagy G. J. The chemical nature of an anticoagulant from tissues. J. Biol. Chem. 250: 433 1944;
    PubMedGoogle Scholar
  • 4 Hecht E, Shapiro D. Sphingosine as an inhibitor of blood clotting. Science 125: 1041 1957;
    CrossrefPubMedGoogle Scholar
  • 5 Tocantins L. M, Carroll R. T. The separation and assay of a lipid antithromboplastin from human brain, blood and plasma fractions. Trans, of the Second Conf. on Blood Clotting and Allied Problems, p. 11. Josiah Macy, Jr. Foundation, New York, N. Y. 1949
    PubMed
  • 6 Turner D. L, Silver M. J, Tocantins L. M. Phospholipid antithromboplastin. II. Preparation and properties. Arch. Biochem. 77: 249 1958;
    CrossrefPubMedGoogle Scholar
  • 7 Barkhan P, Silver M. J, de Costa P. B, Tocantins L. M. Phosphatidyl serine and blood coagulation. Nature 182: 1031 1958;
    CrossrefPubMedGoogle Scholar
  • 7a Silver M. J, Turner D. L, Rodalewicz I, Giordano N, Holburn R, Herb S. F, Luddy F. E. Evaluation of activity of phospholipids in blood coagulation in vitro. Thrombos. Diathes. haemorrh. (Stuttg.) 10: 164 1963;
    PubMedGoogle Scholar
  • 7b Holburn R. R, Silver M. J. Further studies on the inhibitory activity of phosphatidyl serine in blood coagulation in vitro. Fed. Proc. 23: 300 1964;
    PubMedGoogle Scholar
  • 7c Mustard J. F, Medway W, Downie H. G, Rowsell H. C. Effect of intravenous phospholipid containing phosphatidyl serine on blood clotting with particular reference to the Russell’s viper venomtime. Nature 196: 1063 1962;
    CrossrefPubMedGoogle Scholar
  • 8 Troup S. B, Reed C. F, Marinetti G. V, Swisher S. N. Thromboplastic factors in platelets and red blood cells: Observations on their chemical nature and function in in vitro coagulation. J. clin. Invest. 39: 342 1960;
    CrossrefPubMedGoogle Scholar
  • 9 Phillips G. B. The isolation and quantitation of the principal phospholipid components of human serum using chromatography on silicic acid. Biochim. biophys. acta (Amst.) 49: 286 1961;
    CrossrefPubMedGoogle Scholar
  • 10 Nye W. H, WaterHouse C, Marinetti G. V. The phosphatides of human plasma. I. Normal values determined by paper and column chromatography. J. clin. Invest. 40: 1194 1961;
    CrossrefPubMedGoogle Scholar
  • 11 Overman R. S. The chemical purification and mode of action of thromboplastic inhibitor. Trans, of the Second Conf. on Blood Clotting and Allied Problems. New York, N. Y., Josiah Macy, Jr. Foundation, p. 29 1949
    PubMed
  • 12 Rapport M. M. Activation of phospholipid thromboplastin by lecithin. Nature 178: 591 1956;
    PubMedGoogle Scholar
  • 13 Schulz H, Hiepler E. Über die Lokalisierung von gerinnungsphysiologischen Aktivitäten in submikroskopischen Strukturen der Thrombozyten. Klin. Wschr. 37: 273 1959;
    CrossrefPubMedGoogle Scholar
  • 14 Reed G. F, Eden E, Marinetti G. V, Swisher S. N. Studies of erythrocyte phospholipids. J. Lab. clin. Med. 56: 281 1960;
    PubMedGoogle Scholar
  • 15 Marinetti G. V, Erbland J, Kochen J. Quantitative chromatography of phosphatides. Fed. Proc. 16: 837 1957;
    PubMedGoogle Scholar
  • 16 Hanahan D. J. Lipid Chemistry. 28 John Wiley and Sons; New York, N. Y.: 1960
    Google Scholar
  • 17 Alexander B. One stage method for specific prothrombin determination (in plasma or serum). In: Coagulation of Blood. Methods of Study. Ed. Tocantins L. M. 94 Grune and Stratton; New York, N. Y.: 1955
    Google Scholar